Scorpius extends rights plan to March 2025; closes 10M-share public offering for $1.5M

Scorpius Holdings, Inc.

Amendment No. 7 extends stockholder rights plan expiration to March 11, 2025, or earlier redemption/exchange.
Closed public offering of 10,000,000 common shares at $0.15 per share for $1.5M gross proceeds.
Net proceeds will be used for working capital and general corporate purposes.
ThinkEquity acted as sole book-running manager for the offering.

item 1.01 item 3.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Scorpius Holdings, Inc. amended Amendment No. 7 with Continental Stock Transfer & Trust Company (effective 2024-03-11).

Action: amendment
Counterparty: Continental Stock Transfer & Trust Company
Effective: 2024-03-11

Exact text from the filing

On March 11, 2024, Scorpius Holdings, Inc. (formerly known as NightHawk Biosciences, Inc.) (the “Company”) entered into Amendment No. 7 (“Amendment No. 7”) dated March 11, 2024 to the Rights Agreement dated March 11, 2018 (the “Original Rights Agreement”), as amended by Amendment No. 1 thereto (“Amendment No. 1”) dated March 8, 2019, Amendment No. 2 thereto (“Amendment No. 2”) dated March 10, 2020, Amendment No. 3 thereto (“Amendment No. 3”) dated March 8, 2021, Amendment No. 4 thereto (“Amendment No. 4”) dated March 11, 2022, Amendment No. 5 thereto (“Amendment No. 5”) dated March 11, 2023, and Amendment No. 6 thereto (“Amendment No. 6”) dated December 11, 2023 (collectively, the “Rights Agreement”) by and between the Company and Continental Stock Transfer & Trust Company, as rights agent.

View on SEC.gov

565 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001079973-24-000367

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.